Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Journal of Anesthesia, Analgesia and Critical Care ; 2(1):1-1, 2022.
Article in English | BioMed Central | ID: covidwho-1622295

ABSTRACT

After the COVID-19 pandemic outbreak in March 2020, the majority of hospital policies have followed guidelines aimed to prevent the virus transmission and the families’ entry was denied in all hospital wards and intensive care units (ICU). Despite being necessary, such restrictions have been experienced with discomfort and sufferings by the general ICU staff of Treviso Hospital (Italy) and by families of patients. Therefore, from April 2020, a step-by-step project was developed to reactivate contact with COVID-19 patients’ families. The several requests and appeals of intensive care communities and organizations, both nationally and internationally, motivated the Treviso hospital initiative, leading to a model that might be potentially useful to other intensive care units worldwide.

2.
Lorenzoni, Giulia, Sella, Nicolò, Boscolo, Annalisa, Azzolina, Danila, Bartolotta, Patrizia, Pasin, Laura, Pettenuzzo, Tommaso, De Cassai, Alessandro, Baratto, Fabio, Toffoletto, Fabio, De Rosa, Silvia, Fullin, Giorgio, Peta, Mario, Rosi, Paolo, Polati, Enrico, Zanella, Alberto, Grasselli, Giacomo, Pesenti, Antonio, Navalesi, Paolo, Gregori, Dario, Tocco, Martina, Pretto, Chiara, Tamburini, Enrico, Fregolent, Davide, Pirelli, Pier Francesco, Marchesin, Davide, Perona, Matteo, Franchetti, Nicola, Paolera, Michele Della, Simoni, Caterina, Falcioni, Tatiana, Tresin, Alessandra, Schiavolin, Chiara, Schiavi, Aldo, Vathi, Sonila, Sartori, Daria, Sorgato, Alice, Pistollato, Elisa, Linassi, Federico, Gianoli, Sara, Gaspari, Silvia, Gruppo, Francesco, Maggiolo, Alessandra, Giurisato, Elena, Furlani, Elisa, Calore, Alvise, Serra, Eugenio, Pittarello, Demetrio, Tiberio, Ivo, Bond, Ottavia, Michieletto, Elisa, Muraro, Luisa, Peralta, Arianna, Persona, Paolo, Petranzan, Enrico, Zarantonello, Francesco, Graziano, Alessandro, Piasentini, Eleonora, Bernardi, Lorenzo, Pianon, Roberto, Mazzon, Davide, Poole, Daniele, Badii, Flavio, Bosco, Enrico, Agostini, Moreno, Trevisiol, Paride, Farnia, Antonio, Altafini, Lorella, Calò, Mauro Antonio, Meggiolaro, Marco, Lazzari, Francesco, Martinello, Ivan, Papaccio, Francesco, di Gregorio, Guido, Bonato, Alfeo, Sgarabotto, Camilla, Montacciani, Francesco, Alessandra, Parnigotto, Gagliardi, Giuseppe, Ferraro, Gioconda, Ongaro, Luigi, Baiocchi, Marco, Danzi, Vinicio, Zanatta, Paolo, Donadello, Katia, Gottin, Leonardo, Sinigaglia, Ezio, da Ros, Alessandra, Marchiotto, Simonetta, Bassanini, Silvia, Zamperini, Massimo, Daroui, Ivan, Mosaner, Walter.
Journal of Anesthesia, Analgesia and Critical Care ; 1(1):3-3, 2021.
Article in English | BioMed Central | ID: covidwho-1388853
3.
Minerva Anestesiol ; 87(12): 1390-1391, 2021 12.
Article in English | MEDLINE | ID: covidwho-1311489
4.
Am J Hypertens ; 33(10): 944-948, 2020 10 21.
Article in English | MEDLINE | ID: covidwho-574682

ABSTRACT

BACKGROUND: The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients. METHODS: A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020. RESULTS: All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341). CONCLUSIONS: Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.


Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Coronavirus Infections/mortality , Hypertension/complications , Pneumonia, Viral/mortality , Aged , Aged, 80 and over , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Female , Humans , Hypertension/drug therapy , Italy/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL